Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial

BACKGROUND: Exenatide, a glucagon like peptide 1 analog, has been suggested to reduce the cardiovascular disease risk factors, such as body weight, blood pressure and subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM). This was the first randomized, open-label, controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jie, Xian, Tong-Zhang, Wu, Ming-Xiao, Li, Chen, Pan, Qi, Guo, Li-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183674/
https://www.ncbi.nlm.nih.gov/pubmed/32334592
http://dx.doi.org/10.1186/s12933-020-01014-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183674/
https://www.ncbi.nlm.nih.gov/pubmed/32334592
http://dx.doi.org/10.1186/s12933-020-01014-7

Ejemplares similares